Sanofi (SNY) Assets Average (2018 - 2026)
Sanofi (SNY) posted Assets Average of $149.9 billion for Q2 2026, up 0.81% sequentially from $148.7 billion in Q1 2026, and up 7.04% YoY from $140.1 billion in Q2 2025.
Sanofi (SNY) Assets Average (2018 - 2026) Analysis & Trends
Sanofi has reported Assets Average for 3 years, with the latest figure at $149.9 billion in Q2 2026.
- Quarterly Assets Average rose 7.04% year-over-year to $149.9 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $149.9 billion (up 7.04% YoY) and the FY2025 annual result came in at $144.8 billion, up 3.88% from the prior year.
- Assets Average grew to $149.9 billion in Q2 2026 per SNY's latest filing, from $148.7 billion in the prior quarter.
- Over five years, Assets Average peaked at $149.9 billion in Q2 2026 and troughed at $140.1 billion in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.87 Bn | 633.12 Bn | 17.26 Bn | 200.98 Bn |
| 2 | AbbVie | 470.41 Bn | 463.84 Bn | 12.70 Bn | 135.79 Bn |
| 3 | Merck | 376.13 Bn | 368.99 Bn | 12.21 Bn | 129.24 Bn |
| 4 | Novartis Ag | 303.87 Bn | 296.18 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.75 Bn | 252.85 Bn | 12.86 Bn | 114.92 Bn |
| 6 | Amgen | 236.40 Bn | 222.41 Bn | 7.24 Bn | 94.07 Bn |
| 7 | Gilead Sciences | 182.11 Bn | 178.93 Bn | 6.22 Bn | 52.82 Bn |
| 8 | Pfizer | 159.54 Bn | 147.84 Bn | 10.94 Bn | 204.57 Bn |
| 9 | Gsk | 106.30 Bn | 102.13 Bn | 8.24 Bn | 83.80 Bn |
| 10 | Sanofi | 55.15 Bn | 47.77 Bn | 10.79 Bn | 149.95 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 149.95 Bn |
| Mar 31, 2026 | 148.75 Bn |
| Dec 31, 2025 | 149.67 Bn |
| Sep 30, 2025 | 146.59 Bn |
| Jun 30, 2025 | 140.09 Bn |
| Mar 31, 2025 | 140.32 Bn |
| Dec 31, 2018 | 64.51 Bn |
| Sep 30, 2018 | 68.22 Bn |
| Jun 30, 2018 | 135.89 Bn |
| Mar 31, 2018 | 127.35 Bn |